Last reviewed · How we verify
NCT06035471
Can we Use a Simple Blood Test to Reduce Unnecessary Adverse Effects From Radiotherapy by Timely Identification of Radiotherapy-resistant Rectal Cancers? MeD-Seq Rectal Study
trial testing MeD-seq in Pathological Response Rate, Circulating Tumour DNA in 75 participants. Not yet recruiting.
1 June 2026
Quick facts
| Lead sponsor | Erasmus Medical Center |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 75 |
| Start date | 1 October 2023 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 June 2027 |
Drugs / interventions tested
- MeD-seq
Conditions studied
- Pathological Response Rate, Circulating Tumour DNA — all drugs for Pathological Response Rate, Circulating Tumour DNA →
Sponsor
Erasmus Medical Center
Who can join
18 and older, any sex, with Pathological Response Rate, Circulating Tumour DNA. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chemoradiation therapy (CRT) followed by surgery is currently the standard of care to treat patients with locally advanced rectal cancer (LARC). CRT reduces local recurrences, but is associated with significant damage to the surrounding healthy tissue that can severely impact quality of life. Additionally, a proportion of patients (hardly) benefit from CRT. We aim to develop a diagnostic innovation, which can enable a more selective and thereby more effective use of the available therapies for rectal cancer patients. The objective of this study is to investigate whether patients can be identified who will response to CRT prior to start of the CRT in rectal cancer and therefore avoid possible severe side effects in patients who will not reponse on CRT.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Can we use a simple blood test to reduce unnecessary adverse effects from radiotherapy by timely identification of radiotherapy-resistant rectal cancers? MeD-Seq rectal study protocol.
Mens DM, van Rees JM, Wilting SM, Verhoef C. · · 2023 · PMID 38049783 · DOI 10.1186/s12885-023-11671-y
Verify or expand the search:
- PubMed search for NCT06035471
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Erasmus Medical Center trials
Trials by the same sponsor.
- NCT07406269 — Clinical Evaluation of AI Decision Support for Early Rehabilitation After Surgery · NA · not yet recruiting
- NCT07402109 — CBCT Guided Markerless SBRT for Renal Cell Cancer · NA · recruiting
- NCT07383194 — Prediction Models for LDLT Outcomes · not yet recruiting
- NCT07426575 — Evaluating the Usability of New Dialysis Bags · not yet recruiting
- NCT07329296 — The Regenerative Capacity of the Donor Liver After Living Donor Liver Transplantation: an Ambidirectional Cohort Study · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06035471 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Erasmus Medical Center
- Last refreshed: 13 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06035471.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing